220 publications
Brivaracetam (Briviact®)
Zorginstituut Nederland has approved a pharmacotherapeutic report for the medicine brivaracetam (Briviact®), whereby they reached ...
Lumacaftor/ivacaftor (Orkambi®) by Cystic fibrosis
Based on the GVS criteria, lumacaftor/ivacaftor (Orkambi®) can not be replaced by another drug in the GVS. The assessment ...
Eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal haemogloninuria
Zorginstituut Nederland has re-assessed the medicine eculizumab (Soliris®) for the treatment of patients with paroxysmal ...
Levo floxacin (Quinsair®) for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa
Zorginstituut Nederland carried out a marginal assessment of the medicine levofloxacin (Quinsair®), whereby they came to the ...
Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state
Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease
Zorginstituut Nederland has approved a pharmacotherapeutic report for the medicine safinamide (Xadago®). They reached the ...
Onabotulinum toxin A 100 U in cases of idiopathic overactive bladder
Zorginstituut Nederland (the Zorginstituut) concluded that treatment with onabotulin toxin A 100 U does comply with the ...
Ivermectin (Soolantra®) by moderate to severe papulopustulous rosacea
Zorginstituut Nederland advises the Minister of Public Health, Welfare and Sport to include ivermectin (Soolantra®) in the GVS on ...
Eltrombopag (Revolade®) in cases of severe aplastic anaemia
Zorginstituut Nederland has approved a pharmacotherapeutic report for the medicine eltrombopag (Revolade®) in cases of severe ...
Healthcare in the Netherlands
The philosophy underpinning the Dutch healthcare system is based on several more or less universal principles: access to care for ...